Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) recorded 10.60% gain during trading session on February 12th, 2019. The script traded as low as $8.51 and last traded at $8.97. 12.35 million shares changed exchanged hands during trading, a drop of -318.77% from the 30-day average session volume of 2.95M shares. The firm had previously closed at $8.11. The company has $70.74M outstanding shares, price-to-earnings-growth ratio of and a beta of 2.76. The company has a RSI of 57.59, ATR of 0.50 and a volatility of 4.72% this week. VKTX has a 52 week low price of $3.69 and a 52 week high price of $24.00.
Investors have identified the tech company Viking Therapeutics, Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around 634.54M, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Viking Therapeutics, Inc. (VKTX) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For VKTX, the company has in raw cash 169.51 million on their books with 0 currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 180000 total, with 0 as their total liabilities. This figure have given the company a good sense of viability under numerous contexts.
VKTX were able to record 16.08 million as free cash flow during the recently reported quarter of the year, this saw their quarterly net cash flow reduce by 169.51 million. In cash movements, the company had a total of 0 as operating cash flow.
Potential earnings growth for Viking Therapeutics, Inc. (VKTX)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, Viking Therapeutics, Inc. recorded a total of 7.39 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 0.37% coming in sequential stages and their sales for the third quarter increasing by 0.06%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 7.39 million trying to sell their products during the last quarter, with the result yielding a gross income of 0. This allows shareholders to hold on to 70.74M with the revenue now reading 0 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (-0.10 cents a share).
Is the stock of VKTX attractive?
Having a look at the company’s valuation, the company is expected to record -0.46 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on VKTX sounds very interesting.
In related news, 10% Owner LIGAND PHARMACEUTICALS INC sold 262,881 shares of the company’s stock in a transaction that recorded on September 25th, 2019. The sale was performed at an average price of 19.15, for a total value of 5,034,250. As the sale deal closes, the Director LIGAND PHARMACEUTICALS INC now bought 9,500 shares of the company’s stock, valued at 93,261. Also, VP, Finance and Administration MORNEAU MICHAEL sold 21,551 shares of the company’s stock in a deal that was recorded on May 31st, 2019. The shares were sold at an average price of 9.25 per share, with a total market value of 94,035. Following this completion of acquisition, the Director now holds 30,000 shares of the company’s stock, valued at 154,800. In the last 6 months, insiders have changed their ownership in shares of company stock by 11.00%.
2 out of 8 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Viking Therapeutics, Inc. stock. 0 analysts has assigned a Sell rating on the VKTX stock. The 12-month mean consensus price target for the company’s shares has been set at $29.79.